Post-licensure safety surveillance for ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Post-licensure safety surveillance for prevenar 13 (r) in france
Author(s) :
Agier, M-S [Auteur]
Marchand, S. [Auteur]
Paret, N. [Auteur]
Gautier, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Jonville-Bera, Annie-Pierre [Auteur]
Marchand, S. [Auteur]
Paret, N. [Auteur]
Gautier, Sophie [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Jonville-Bera, Annie-Pierre [Auteur]
Journal title :
Archives de pediatrie . organe officiel de la Societe francaise de pediatrie
Abbreviated title :
Arch. Pediatr.
Volume number :
24
Pages :
439-444
Publication date :
2017-05-01
ISSN :
0929-693X
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13®
METHODS: Analysis of all adverse events reported with Prevenar 13®
RESULTS: In 4 years and 4 months, 376 AEs, including ...
Show more >OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13® METHODS: Analysis of all adverse events reported with Prevenar 13® RESULTS: In 4 years and 4 months, 376 AEs, including 252 severe (67%), were recorded, 83 of which occurred following an injection of Prevenar 13® CONCLUSIONS: In many cases, Prevenar 13®®® CONCLUSIONS: Since its release in 2010, the Prevenar 13®Show less >
Show more >OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13® METHODS: Analysis of all adverse events reported with Prevenar 13® RESULTS: In 4 years and 4 months, 376 AEs, including 252 severe (67%), were recorded, 83 of which occurred following an injection of Prevenar 13® CONCLUSIONS: In many cases, Prevenar 13®®® CONCLUSIONS: Since its release in 2010, the Prevenar 13®Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Research team(s) :
Troubles cognitifs dégénératifs et vasculaires
Submission date :
2019-11-27T13:03:01Z